Demographic data of the first cohort of patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA)
| PsA (n = 16) | RA (n = 13) | |
| Female, no (%) | 6 (38%) | 6 (46%) |
| Age in years, mean (range) | 46.5 (22–64) | 52.6 (38–69) |
| Disease duration in months, mean (range) | 120 (39–284) | 137 (10–278) |
| RF and/or anti-CCP positive, no (%) | 2 (13%) | 13 (100%) |
| Erosions, no (%) of patients | 8 (50%) | 11 (88%) |
| ESR mm/h, median (IQR) | 21.5 (7.3–32.3) | 28.0 (9.5–47.5) |
| CRP mg/litre, median (IQR) | 10.4 (2.5–23.7) | 7.0 (3.5–35.5) |
| Methotrexate dose (mg), mean (SD) | 16.7 (7.2) | 20.0 (4.3) |
Patients with RA were more often RF and/or anti-CCP positive than patients with PsA. No other significant differences in the clinical data between patients with RA and PsA were detectable.
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range (25th–75th percentile); RF, rheumatoid factor.